Topoisomerase IIα gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer

被引：18

作者：

Buzdar, Aman J. ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 16期

关键词：

D O I：

10.1200/JCO.2006.05.9113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2409 / 2411

页数：3

共 29 条

[11]

Durbecq V, 2004, INT J ONCOL, V25, P1473

[12] Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [J].

Henderson, IC ;

Berry, DA ;

Demetri, GD ;

Cirrincione, CT ;

Goldstein, LJ ;

Martino, S ;

Ingle, JN ;

Cooper, MR ;

Hayes, DF ;

Tkaczuk, KH ;

Fleming, G ;

Holland, JF ;

Duggan, DB ;

Carpenter, JT ;

Frei, E ;

Schilsky, RL ;

Wood, WC ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :976-983

[13] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[14] HER-2/neu and topoisomerase IIα in breast cancer [J].

Järvinen, TAH ;

Liu, ET .

BREAST CANCER RESEARCH AND TREATMENT, 2003, 78 (03) :299-311

[15]

Järvinen TAH, 1999, GENE CHROMOSOME CANC, V26, P142

[16] Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer [J].

Järvinen, TAH ;

Tanner, M ;

Rantanen, V ;

Bärlund, M ;

Borg, Å ;

Grénman, S ;

Isola, J .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03) :839-847

[17] Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group [J].

Knoop, AS ;

Knudsen, H ;

Balslev, E ;

Rasmussen, BB ;

Overgaard, J ;

Nielsen, KV ;

Schonau, A ;

Gunnarsdóttir, K ;

Olsen, KE ;

Mouridsen, H ;

Ejlertsen, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7483-7490

[18] Adjuvant docetaxel for node-positive breast cancer [J].

Martin, M ;

Pienkowski, T ;

Mackey, J ;

Pawlicki, M ;

Guastalla, JP ;

Weaver, C ;

Tomiak, E ;

Al-Tweigeri, T ;

Chap, L ;

Juhos, E ;

Guevin, R ;

Howell, A ;

Fornander, T ;

Hainsworth, J ;

Coleman, R ;

Vinholes, J ;

Modiano, M ;

Pinter, T ;

Tang, SC ;

Colwell, B ;

Prady, C ;

Provencher, L ;

Walde, D ;

Rodriguez-Lescure, A ;

Hugh, J ;

Loret, C ;

Rupin, M ;

Blitz, S ;

Jacobs, P ;

Murawsky, M ;

Riva, A ;

Vogel, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2302-2313

[19] erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer [J].

Paik, SM ;

Bryant, J ;

Park, CH ;

Fisher, B ;

Tan-Chiu, E ;

Hyams, D ;

Fisher, ER ;

Lippman, ME ;

Wickerham, DL ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1361-1370

[20] The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells [J].

Pegram, MD ;

Finn, RS ;

Arzoo, K ;

Beryt, M ;

Pietras, RJ ;

Slamon, DJ .

ONCOGENE, 1997, 15 (05) :537-547

← 1 2 3 →